anonymous
Guest
anonymous
Guest
IMHO ( in my humble opinion) it means that this is a different scenario than the classic "pharma101". 351k ( assuming "interchangeablilty"; look that up as well) puts biosims in more of a conventional generic market paradigm. The implication would be more price point sensitivity than a classic value added approach/"surround sound" marketing approach. Customers may want better prices AND the support services. Who knows. The biosim market is just getting underway. Lots of reference drugs going off patent lots of companies developing biosims. It's a whole new normal. I do think however that pricing will be a key strategic consideration. But what do I know. I'm the same gal who thought Trump had zero chance of getting elected.
Ditto about Trump